AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
종목 코드 ABBV
회사 이름AbbVie Inc
상장일Jan 02, 2013
CEOMichael (Robert A)
직원 수55000
유형Ordinary Share
회계 연도 종료Jan 02
주소1 N Waukegan Rd
도시NORTH CHICAGO
증권 거래소NASDAQ OMX NASDAQ Basic NYSE
국가United States of America
우편 번호60064
전화18479327900
웹사이트https://www.abbvie.com/
종목 코드 ABBV
상장일Jan 02, 2013
CEOMichael (Robert A)